These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29521318)

  • 1. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis.
    Park IS; Lee SB; Song SH; Seong EY; Kim IY; Rhee H; Kim MJ; Lee DW
    Anatol J Cardiol; 2018 Mar; 19(3):225-226. PubMed ID: 29521318
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
    Vrkić Kirhmajer M; Macolić Šarinić V; Šimičević L; Ladić I; Putarek K; Banfić L; Božina N
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):509-518. PubMed ID: 29734517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
    Dineen M; Hansen E; Guancial E; Sievert L; Sahasrabudhe D
    J Oncol Pharm Pract; 2018 Jun; 24(4):314-318. PubMed ID: 28355968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin.
    Martín Navarro JA; Gutiérrez Sánchez MJ; Petkov Stoyanov V; Jiménez Herrero MC
    Nefrologia (Engl Ed); 2019; 39(4):448-450. PubMed ID: 30798999
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins.
    Danielak D; Karaźniewicz-Łada M; Główka F
    Drugs; 2018 Jul; 78(11):1105-1112. PubMed ID: 30003466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Sardella G; Mancone M; Stio RE; Cavallo E; Di Roma A; Colantonio R; Calcagno S
    Circulation; 2017 Aug; 136(6):602-604. PubMed ID: 28784829
    [No Abstract]   [Full Text] [Related]  

  • 7. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry.
    Zeymer U; Cully M; Hochadel M
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):205-210. PubMed ID: 29878086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial.
    Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
    J Cardiovasc Transl Res; 2018 Feb; 11(1):42-49. PubMed ID: 29344840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse alveolar hemorrhage associated with ticagrelor therapy after percutaneous coronary intervention.
    Yılmaz S; Kılıç O; Yaylalı YT
    Anatol J Cardiol; 2018 Jul; 20(1):60-61. PubMed ID: 29952365
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study.
    Kubica J; Adamski P; Buszko K; Kubica A; Kuliczkowski W; Fabiszak T; Jilma B; Alexopoulos D; Paciorek P; Navarese EP
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):152-157. PubMed ID: 29040445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design.
    Brugaletta S; Gomez-Lara J; Caballero J; Ortega-Paz L; Teruel L; Jimenez Fernandez M; Romaguera R; Alcalde Martinez V; Ñato M; Molina Navarro E; Gomez-Hospital JA; Correa Vilches C; Joyera M; Cequier A; Sabate M
    Catheter Cardiovasc Interv; 2018 Jan; 91(1):1-6. PubMed ID: 28707316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?
    Aradi D; Dezsi D; Veress G; Merkely B
    Curr Vasc Pharmacol; 2018; 16(5):446-450. PubMed ID: 29345592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Ticagrelor Versus Clopidogrel in Patients With Prior Myocardial Infarction.
    Alexopoulos D; Despotopoulos S; Xanthopoulou I; Davlouros P
    J Am Coll Cardiol; 2017 Oct; 70(16):2091-2092. PubMed ID: 29025562
    [No Abstract]   [Full Text] [Related]  

  • 17. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.
    Raposeiras-Roubín S; Caneiro Queija B; D'Ascenzo F; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Varbella F; Tomassini F; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Baz-Alonso JA; Calvo-Iglesias F; Valdés M; Cequier Á; Gaita F; Alexopoulos D; Íñiguez-Romo A; Abu-Assi E
    Rev Esp Cardiol (Engl Ed); 2019 Mar; 72(3):215-223. PubMed ID: 30029980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).
    Mangiacapra F; Panaioli E; Colaiori I; Ricottini E; Lauria Pantano A; Pozzilli P; Barbato E; Di Sciascio G
    Circulation; 2016 Sep; 134(11):835-7. PubMed ID: 27619717
    [No Abstract]   [Full Text] [Related]  

  • 20. THEMIS and THEMIS-PCI.
    Bhatt DL; Steg PG
    Eur Heart J; 2019 Nov; 40(41):3378-3381. PubMed ID: 31545357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.